Funding

[Funding alert] Switzerland-based Nouscom Secures €67.5M in Series C Round Funding

Nov 15, 2023 | By Startup Rise EU

Switzerland-based Nouscom secures €67.5M in series C round funding. Leading the round were Andera Partners, Bpifrance (via its InnoBio 2 fund), and M Ventures. Other participants included Revelation Partners, Panakès Partners, XGen Ventures, Indaco Venture Partners, and current investors Versant Ventures, EQT Life Sciences, and 5AM Ventures.

Switzerland-based Nouscom secures €67.5M in series C round funding. Leading the round were Andera Partners, Bpifrance (via its InnoBio 2 fund), and M Ventures. Other participants included Revelation Partners, Panakès Partners, XGen Ventures, Indaco Venture Partners, and current investors Versant Ventures, EQT Life Sciences, and 5AM Ventures.

Alongside the funding, members from M Ventures, Bpifrance, and Andera Partners joined the Nouscom Board of Directors. The business plans to use the money to fund the expansion and advancement of its fully owned clinical pipeline in order to accomplish certain clinical value catalysts, such as:

Read also - UK-based Accenture Acquire 6point6

Readout from a current randomised Phase 2 clinical trial for mismatch repair/microsatellite instabilities (dMMR/MSI) metastatic colorectal cancer (mCRC) using pembrolizumab and NOUS-209, an off-the-shelf vaccination targeting 209 common neoantigens.

RECOMMENDED FOR YOU

recomd
Funding
[Funding alert] London-based TRIVER Secures further €22.9 Million in Funding
Startup Rise EU
Nov 21, 2023
recomd
Funding
[Funding alert] Barcelona-based Sateliot Raises €6M in Funding
Startup Rise EU
Jan 12, 2024
recomd
Recent Articles
[Funding alert] Copenhagen-based Meo Raises €1.67 Million in Funding
Startup Rise EU
Mar 5, 2024

The present report provides the final analysis of the current Phase 1b trial, which is examining the ability to intercept, prevent, or postpone cancer before it arises in Lynch Syndrome (LS) carriers by the use of NOUS-209 monotherapy.

Read also - SUPPLYZ Rebrands as RESONIKS and Secures Investment from Kvanted

LS carriers are more likely to acquire some cancers because to a genetic predisposition. At the most recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting, encouraging preliminary findings from this study were presented in a Late-breaking Abstract.

Nouscom, a clinical-stage immuno-oncology business led by CEO Marina Udier, is creating both customised and off-the-shelf cancer immunotherapies.

Read also - Chasse sur Rhône-based Recyc’ELIT Raises €3.2M in Funding

Its unique viral vector technology has been clinically shown to safely and potently stimulate the immune system while encoding for huge payloads of neoantigens or other immunomodulators.

About Nouscom

Additionally, VAC-85135, an off-the-shelf immunotherapy created under a multi-project agreement and presently being assessed in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms supported by Janssen Research & Development and Bristol Myers Squibb, is exclusively out-licensed by Nouscom.

Read also - London-based Letoon Holding Secures £20M in Funding

Recommended Stories for You

story
Norway

[Funding alert] Oslo-based proptech Startup Plaace Raises €885k in Funding

Startup Rise EU Jan 15, 2024

story
Funding

[Funding alert] Paris-based Groover Secures $8 Million in Series A Round Funding

Team SR Feb 13, 2024

story
Funding

[Funding alert] Cologne-based Metal Trading Platform METYCLE Secures €4.7 Million in Funding

Startup Rise EU Dec 14, 2023

story
Funding

Adam Funding news – Czech-based Adam Secures €3 Million in late Seed Funding

Startup Rise EU Jul 16, 2024

story
Belgium

[Funding alert] Leuven-based VaultSpeed Raises €15.1 Million Series A Round Funding

Startup Rise EU Nov 16, 2023

story
France

[Funding alert] French-based Legal AI Company Jimini AI Secures €1.9 Million in Seed Funding

Startup Rise EU Nov 13, 2023